Skip to main content
4DMEDICAL LIMITED logo

4DMEDICAL LIMITED — Investor Relations & Filings

Ticker · 4DX ISIN · AU0000095416 LEI · 9845000A8F12A6A6FD75 ASX Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2023-11-21 Capital/Financing Update
Country AU Australia
Listing ASX 4DX

About 4DMEDICAL LIMITED

https://4dmedical.com/

4DMedical Limited develops non-invasive respiratory imaging solutions centered on its proprietary XV Technology. This platform utilizes advanced algorithms to transform standard X-ray sequences into four-dimensional quantitative data, visualizing regional lung function in motion. The flagship XV Lung Ventilation Analysis Software (XV LVAS) provides clinicians with detailed maps of airflow distribution throughout the respiratory cycle, facilitating the early detection and monitoring of chronic conditions such as COPD, asthma, and interstitial lung disease. By providing objective, high-resolution insights into lung ventilation without the limitations of traditional pulmonary function tests, the company's cloud-based diagnostic tools aim to improve clinical workflows and patient management. The integration of artificial intelligence further enhances its capability to deliver precise, automated lung tissue analysis.

Recent filings

Filing Released Lang Actions
4DX signs SaaS contracts to expand into Detroit & Memphis 2 pages 216.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 22 November 2023, describing 4DMedical signing SaaS contracts to expand access to their XV LVAS® technology in Detroit and Memphis. It discusses business developments, contract signings, and market expansion following reimbursement approval by CMS. There are no financial statements, earnings data, or detailed financial analysis present. The document is a corporate announcement about new contracts and business updates rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Earnings Release, or Interim Report. It is a typical Capital/Financing Update as it relates to business expansion and contract signings that impact company revenue streams.
2023-11-21 English
4DMedical receives U.S. FDA clearance for CT LVAS 3 pages 358.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 20th November 2023 about 4DMedical receiving U.S. FDA clearance for its CT LVAS™ product. It discusses regulatory clearance, product details, market implications, and upcoming commercial activities. The text is an announcement of a regulatory milestone and commercial update rather than a detailed financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is not a report publication announcement since it is a substantive announcement itself, not just a notice of report availability. The content fits best under Capital/Financing Update (CAP) as it relates to regulatory clearance impacting the company's product commercialization and market access, which is a form of capital/financing update relevant to investors and the market.
2023-11-19 English
U.S. CMS Approves Reimbursement for 4DMedical 2 pages 234.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 13 November 2023, detailing the U.S. Centers for Medicare & Medicaid Services (CMS) approval of reimbursement for 4DMedical's XV LVAS® procedure. It discusses the assignment of a reimbursement rate and the impact on commercialisation and adoption of the technology. The content is a corporate announcement about a regulatory and commercial milestone rather than a financial report, earnings release, or detailed investor presentation. It does not contain financial statements or detailed financial data. The document is approximately 5913 characters, which is relatively short and focused on a specific update. This fits best under Capital/Financing Update (CAP) as it relates to reimbursement and funding developments impacting the company's commercial prospects and capitalisation potential. It is not an earnings release or annual/interim report, nor a regulatory filing or report publication announcement. Therefore, the most appropriate classification is CAP with high confidence.
2023-11-12 English
Presentation to Bell Potter Healthcare Conference 44 pages 4.8MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated 13 November 2023, providing a presentation to the Bell Potter Healthcare Conference. It contains detailed information about the company's achievements, commercialisation, regulatory milestones, reimbursement processes, and investment opportunities. The content is structured as a presentation with slides, disclaimers, and forward-looking statements. There are no full financial statements or detailed financial analysis typical of annual or interim reports. It is not a transcript of a call, nor an audit report, nor a regulatory filing or voting announcement. The document is clearly a presentation aimed at investors and stakeholders, focusing on company strategy, market position, and financial highlights. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2023-11-12 English
Change of Director's Interest Notice 3 pages 250.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in the director Andreas Fouras's relevant interests in securities, including direct and indirect holdings, option grants, and related contracts. The content focuses on insider share transactions by a company director, including the nature and number of securities held before and after the change, and the circumstances of the change. There is no financial performance data, earnings information, or report publication details. This matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades). The document length is about 4850 characters, which is consistent with a detailed insider trading notice rather than a full financial report or announcement. Therefore, the correct classification is DIRS (Director's Dealing).
2023-11-05 English
Notification regarding unquoted securities - 4DX 9 pages 34.9KB
Share Issue/Capital Change Classification · 100% confidence The document is a detailed notification about the issue of unquoted equity securities, specifically options granted under an employee incentive scheme. It includes information about the number of securities issued, the exercise price, expiry date, and details about the key management personnel receiving the securities. The document references compliance with ASX listing rules and shareholder approval at the Annual General Meeting. This type of document is a formal announcement of a share issue or capital change, not a full financial report or earnings release. It fits the category of announcements regarding new share issues or capital changes rather than other categories like Annual Report or Earnings Release.
2023-11-05 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.